Michel Vallée
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michel Vallée has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
Alain Milot
Department of Medicine, Université Laval, Québec, Quebec, Canada
13 shared publications- Ernesto L. Schiffrin
Department of Medicine, McGill University
13 shared publications Marcel Ruzicka
Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
13 shared publications- Michael Douglas Hill
University of Calgary
13 shared publications - Raj Padwal
University of Alberta
13 shared publications Simon W. Rabkin
Vancouver Hospital, University of British Columbia, Vancouver, British Columbia, Canada
13 shared publications
Latest Publications
- Open Access
- 1 August 2021
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 14, 301-311
Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia
Population-based studies have shown that most patients with advanced chronic kidney disease (CKD) do not have optimal phosphate levels. Meta-analyses suggest that there is a morbidity and mortality benefit associated with the lowering of serum phosphate levels. However, to date there is no conclusive evidence from randomized controlled trials (RCTs) that lowering serum phosphate levels reduces the risk of morbidity and mortality. However, hyperphosphatemia may pose a risk to patients and treatment should be considered. We therefore sought to conduct a multidisciplinary review to help guide clinical decision-making pending results of ongoing RCTs. Restricting dietary phosphate intake is frequently the first step in the management of hyperphosphatemia. Important considerations when proposing dietary restriction include the patient’s socioeconomic status, lifestyle, dietary preferences, comorbidities, and nutritional status. While dietary phosphate restriction may be a valid strategy in certain patients, serum phosphate reductions achieved solely by limiting dietary intake are modest and should be considered in conjunction with other interventions. Conventional dialysis is also typically insufficient; however phosphate removal may be augmented by increased frequency or duration of dialysis, or through enhanced methods such as hemodiafiltration. Phosphate binders have been shown to reduce absorption of dietary phosphate and lower serum phosphate levels. There are several phosphate binders available, and while they all lower phosphate levels to variable degrees, they differ with respect to their pill burden, potential to induce or exacerbate vascular calcification or ectopic calcification, tissue accumulation, safety, and tolerability. The widespread treatment of hyperphosphatemia requires convincing data from RCTs to ascertain whether lowering serum phosphate levels improves patient-important outcomes, as well as the optimal method and degree of phosphate control. In the interim, the decision and approach used to treat hyperphosphatemia should be based on the best available data, as well as patient needs and clinical judgment.
- 1 August 2021
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 14, 301-311
Open AccessMultidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia
Population-based studies have shown that most patients with advanced chronic kidney disease (CKD) do not have optimal phosphate levels. Meta-analyses suggest that there is a morbidity and mortality benefit associated with the lowering of serum phosphate levels. However, to date there is no conclusive evidence from randomized controlled trials (RCTs) that lowering serum phosphate levels reduces the risk of morbidity and mortality. However, hyperphosphatemia may pose a risk to patients and treatment should be considered. We therefore sought to conduct a multidisciplinary review to help guide clinical decision-making pending results of ongoing RCTs. Restricting dietary phosphate intake is frequently the first step in the management of hyperphosphatemia. Important considerations when proposing dietary restriction include the patient’s socioeconomic status, lifestyle, dietary preferences, comorbidities, and nutritional status. While dietary phosphate restriction may be a valid strategy in certain patients, serum phosphate reductions achieved solely by limiting dietary intake are modest and should be considered in conjunction with other interventions. Conventional dialysis is also typically insufficient; however phosphate removal may be augmented by increased frequency or duration of dialysis, or through enhanced methods such as hemodiafiltration. Phosphate binders have been shown to reduce absorption of dietary phosphate and lower serum phosphate levels. There are several phosphate binders available, and while they all lower phosphate levels to variable degrees, they differ with respect to their pill burden, potential to induce or exacerbate vascular calcification or ectopic calcification, tissue accumulation, safety, and tolerability. The widespread treatment of hyperphosphatemia requires convincing data from RCTs to ascertain whether lowering serum phosphate levels improves patient-important outcomes, as well as the optimal method and degree of phosphate control. In the interim, the decision and approach used to treat hyperphosphatemia should be based on the best available data, as well as patient needs and clinical judgment.
- Open Access
- 1 January 2021
- Published by Open Access Text Pvt, Ltd. in Clinical and Medical Reports
- Vol. 4 (1)
A case of secondary hyperparathyroidism in a patient on hemodialysis with parathormone levels within the targets and high total alkaline phosphatase
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.
- 1 January 2021
- Published by Open Access Text Pvt, Ltd. in Clinical and Medical Reports
- Vol. 4 (1)
Open AccessA case of secondary hyperparathyroidism in a patient on hemodialysis with parathormone levels within the targets and high total alkaline phosphatase
OA Text is an independent open-access scientific publisher showcases innovative research and ideas aimed at improving health by linking research and practice to the benefit of society.
- 1 July 2020
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 58 (07) , 404-405
Aminoglycosides administration at the end of the hemodialysis session: A pharmacokinetic failure?
- 1 July 2020
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 58 (07) , 404-405
Aminoglycosides administration at the end of the hemodialysis session: A pharmacokinetic failure?
- 1 November 2019
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 57 (11) , 571-574
The usefulness of thiazide and thiazide-like diuretics in advanced chronic kidney disease
- 1 November 2019
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 57 (11) , 571-574
The usefulness of thiazide and thiazide-like diuretics in advanced chronic kidney disease
- 1 May 2018
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 34 (5) , 665-669
The 2017 American College of Cardiology/American Heart Association vs Hypertension Canada High Blood Pressure Guidelines and Potential Implications
- 1 May 2018
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 34 (5) , 665-669
The 2017 American College of Cardiology/American Heart Association vs Hypertension Canada High Blood Pressure Guidelines and Potential Implications
- Top Cited PapersOpen Access
- 1 May 2018
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 34 (5) , 506-525
Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children
- 1 May 2018
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 34 (5) , 506-525
Top Cited PapersOpen AccessHypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children
- 1 April 2018
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 42 (2) , 205-208
Single-Pill Combinations in the Treatment of Hypertension in Adults: Beyond Convenience
- 1 April 2018
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 42 (2) , 205-208
Single-Pill Combinations in the Treatment of Hypertension in Adults: Beyond Convenience
- Top Cited Papers
- 1 May 2017
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 33 (5) , 557-576
Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults
- 1 May 2017
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 33 (5) , 557-576
Top Cited PapersHypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults
- Open Access
- 13 March 2017
- Published by Wiley in Journal of Transplantation
- Vol. 2017, 1-6
Retrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation
Objectives.The primary objective of this study is to evaluate the use of cinacalcet in the management of hyperparathyroidism in kidney transplant recipients. The secondary objective is to identify baseline factors that predict cinacalcet use after transplantation.Methods.In this single-center retrospective study, we conducted a chart review of all patients having been transplanted from 2003 to 2012 and having received cinacalcet up to kidney transplantation and/or thereafter.Results.Twenty-seven patients were included with a mean follow-up ofyears. Twenty-one were already taking cinacalcet at the time of transplantation. Cinacalcet was stopped within the first month in 12 of these patients of which 7 had to restart therapy. The main reason for restarting cinacalcet was hypercalcemia. Length of treatment wasmonths. There were only 3 cases of mild hypocalcemia. There was no statistically significant association between baseline factors and cinacalcet status a year later.Conclusions.Discontinuing cinacalcet within the first month of kidney transplantation often leads to hypercalcemia. Cinacalcet appears to be an effective treatment of hypercalcemic hyperparathyroidism in kidney transplant recipients. Further studies are needed to evaluate safety and long-term benefits.- 13 March 2017
- Published by Wiley in Journal of Transplantation
- Vol. 2017, 1-6
Open AccessRetrospective Study Looking at Cinacalcet in the Management of Hyperparathyroidism after Kidney Transplantation
Objectives.The primary objective of this study is to evaluate the use of cinacalcet in the management of hyperparathyroidism in kidney transplant recipients. The secondary objective is to identify baseline factors that predict cinacalcet use after transplantation.Methods.In this single-center retrospective study, we conducted a chart review of all patients having been transplanted from 2003 to 2012 and having received cinacalcet up to kidney transplantation and/or thereafter.Results.Twenty-seven patients were included with a mean follow-up ofyears. Twenty-one were already taking cinacalcet at the time of transplantation. Cinacalcet was stopped within the first month in 12 of these patients of which 7 had to restart therapy. The main reason for restarting cinacalcet was hypercalcemia. Length of treatment wasmonths. There were only 3 cases of mild hypocalcemia. There was no statistically significant association between baseline factors and cinacalcet status a year later.Conclusions.Discontinuing cinacalcet within the first month of kidney transplantation often leads to hypercalcemia. Cinacalcet appears to be an effective treatment of hypercalcemic hyperparathyroidism in kidney transplant recipients. Further studies are needed to evaluate safety and long-term benefits.